While CD40ML increased CLL cellular CD86 expression, a marker for activation, their activation status was not significantly different upon GRN treatment, both in the absence and in presence of CD40ML (Figure 2d). The gene discussed is CD86; the disease is B-cell chronic lymphocytic leukemia.